Medstone panel review.
This article was originally published in The Gray Sheet
Executive Summary
FDA's Gastroenterology and Urology Devices Panel is slated to review a premarket approval application for Medstone's lithotripter in conjunction with Actigall (ursodiol USP) for non-invasive treatment of gallstones, the company says. FDA informed the firm on March 6 that it had filed the PMA, Medstone notes. Data included in the PMA shows adjunctive lithotripter use "speeds up clearance of the gallstones and results in higher success rates compared to drug therapy alone," the company claims...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.